Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK‐BR‐3 breast cancer cell proliferation

Abstract.  Objectives: The potential of epidermal growth factor receptor (EGFR)‐ and Her2‐targeted antibodies Cetuximab, Pertuzumab and Trastuzumab, used in combination to inhibit cell proliferation of breast cancer cells in vitro, has not been extensively investigated. It is anticipated that there...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Prolif
Autors principals: Brockhoff, G., Heckel, B., Schmidt‐Bruecken, E., Plander, M., Hofstaedter, F., Vollmann, A., Diermeier, S.
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2007
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496387/
https://ncbi.nlm.nih.gov/pubmed/17635517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2184.2007.00449.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars